Home Clinical Trials Dosing MOA Resources Advancing PF care Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required 01/23/2025 | Author: Boehringer Ingelheim Document ID: PC-IME-100592 | Expiry Date: 09/13/2026 Resources OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required How to Suspect ILD Related Product Item Read more 0:58 How to Suspect ILD PC-IME-100576 (August 2026 ) Watch now Opens in new tab Home Respiratory OFEV Resources OFEV®(nintedanib) is a Recommended Treatment Option at Diagnosis for SSc-ILD Patients If Pharmacological Treatment is Required